Rafaella Cleto Penteado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rafaella Cleto Penteado has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Robert N. Weinreb
Hamilton Glaucoma Center, Shiley Eye Institute and Department of Ophthalmology, University of California San Diego, La Jolla, California, USA
6 shared publications Sasan Moghimi
From the Hamilton Glaucoma Center (N.W.E., S.M., R.C.P., E.G., N.B., J.P., J.L.D., A.C., M.S., V.R., R.N.W.), Shiley Eye Institute, and the Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, USA
5 shared publications- Christopher Bowd
Hamilton Glaucoma Center and Division of Ophthalmology Informatics and Data Science, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, CA 92037, USA
3 shared publications Elham Ghahari
From the Hamilton Glaucoma Center (N.W.E., S.M., R.C.P., E.G., N.B., J.P., J.L.D., A.C., M.S., V.R., R.N.W.), Shiley Eye Institute, and the Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, USA
3 shared publicationsDiya Yang
Beijing Tongren Eye Center (D.Y.), Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing, China
2 shared publicationsHuiyuan Hou
Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California
2 shared publications
Latest Publications
- Open Access
- 24 July 2024
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 60 (1) , e59-e64
Orbital decompression following treatment with teprotumumab for thyroid eye disease
- 24 July 2024
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 60 (1) , e59-e64
Open AccessOrbital decompression following treatment with teprotumumab for thyroid eye disease
- 6 May 2022
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 241, 120-129
Comparison of the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density: A Randomized Clinical Trial
- 6 May 2022
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 241, 120-129
Comparison of the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density: A Randomized Clinical Trial
- 1 March 2022
- Published by Elsevier in Ophthalmology Glaucoma
- Vol. 5 (2) , 170-178
Macular Thickness and Microvasculature Loss in Glaucoma Suspect Eyes
- 1 March 2022
- Published by Elsevier in Ophthalmology Glaucoma
- Vol. 5 (2) , 170-178
Macular Thickness and Microvasculature Loss in Glaucoma Suspect Eyes
- 13 January 2020
- Published by Elsevier in Ophthalmology
- Vol. 127 (8) , 1043-1052
Ganglion Cell Complex Thickness and Macular Vessel Density Loss in Primary Open-Angle Glaucoma
- 13 January 2020
- Published by Elsevier in Ophthalmology
- Vol. 127 (8) , 1043-1052
Ganglion Cell Complex Thickness and Macular Vessel Density Loss in Primary Open-Angle Glaucoma
- Top Cited Papers
- 1 July 2019
- Published by Elsevier in Ophthalmology
- Vol. 126 (7) , 980-988
Measurement Floors and Dynamic Ranges of OCT and OCT Angiography in Glaucoma
- 1 July 2019
- Published by Elsevier in Ophthalmology
- Vol. 126 (7) , 980-988
Top Cited PapersMeasurement Floors and Dynamic Ranges of OCT and OCT Angiography in Glaucoma
- 1 November 2018
- Published by Elsevier in Ophthalmology
- Vol. 125 (11) , 1720-1728
Macular and Optic Nerve Head Vessel Density and Progressive Retinal Nerve Fiber Layer Loss in Glaucoma
- 1 November 2018
- Published by Elsevier in Ophthalmology
- Vol. 125 (11) , 1720-1728
Macular and Optic Nerve Head Vessel Density and Progressive Retinal Nerve Fiber Layer Loss in Glaucoma
- 1 August 2017
- Published by Elsevier in Ophthalmology
- Vol. 124 (8) , 1249-1251
Aqueous Angiography: Aqueous Humor Outflow Imaging in Live Human Subjects
- 1 August 2017
- Published by Elsevier in Ophthalmology
- Vol. 124 (8) , 1249-1251
Aqueous Angiography: Aqueous Humor Outflow Imaging in Live Human Subjects
- Open Access
- 1 August 2013
- Published by Wiley in Journal of Ophthalmology
- Vol. 2013, 1-4
Expression of the Metastasis Suppressor KAI1 in Uveal Melanoma
Introduction. Uveal melanoma (UM) is an intraocular tumor that leads to metastatic disease in approximately 50% of afflicted patients. There is no efficacious treatment for metastatic disease in this cancer. Identification of markers that can offer prognostic and therapeutic value is a major focus in this field at present. KAI1 is a metastasis suppressor gene that has been reported to play a role in various human malignancies, although it has not previously been evaluated in UM.Purpose. To investigate the expression of KAI1 in UM and its potential value as a prognostic marker.Materials and Methods. 18 cases of human primary UM were collected and immunostained for KAI1 expression. A pathologist evaluated staining intensity and distribution semiquantitatively. Each case was categorized as group 1 (low staining) or group 2 (high staining).Results. In group 2, two of the 12 cases presented with metastasis. Conversely, in group 1, five out of 6 cases had metastasis. The mean follow-up of patients who did not develop metastasis was 81.81 months (median: 75 months) versus 42.14 months (median: 44 months) for patients with metastasis.Conclusions. KAI1 is a promising candidate marker that may offer prognostic value in UM; it may also represent a therapeutic target in metastatic disease.
- 1 August 2013
- Published by Wiley in Journal of Ophthalmology
- Vol. 2013, 1-4
Open AccessExpression of the Metastasis Suppressor KAI1 in Uveal Melanoma
Introduction. Uveal melanoma (UM) is an intraocular tumor that leads to metastatic disease in approximately 50% of afflicted patients. There is no efficacious treatment for metastatic disease in this cancer. Identification of markers that can offer prognostic and therapeutic value is a major focus in this field at present. KAI1 is a metastasis suppressor gene that has been reported to play a role in various human malignancies, although it has not previously been evaluated in UM.Purpose. To investigate the expression of KAI1 in UM and its potential value as a prognostic marker.Materials and Methods. 18 cases of human primary UM were collected and immunostained for KAI1 expression. A pathologist evaluated staining intensity and distribution semiquantitatively. Each case was categorized as group 1 (low staining) or group 2 (high staining).Results. In group 2, two of the 12 cases presented with metastasis. Conversely, in group 1, five out of 6 cases had metastasis. The mean follow-up of patients who did not develop metastasis was 81.81 months (median: 75 months) versus 42.14 months (median: 44 months) for patients with metastasis.Conclusions. KAI1 is a promising candidate marker that may offer prognostic value in UM; it may also represent a therapeutic target in metastatic disease.